Denali Therapeutics Inc.
DNLI· Nasdaq
Released Feb 27, 2025, after the close
10-K filed Feb 27, 2025, 58 days after period end · 0001714899-25-000066
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $10.26M | $12.51M |
| Net Income | -$114.75M |
Denali Therapeutics Inc. · CIK 1714899 · Engraved from SEC EDGAR
| -$119.47M |
| -$98.68M |
| -$75.26M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.